CASI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CASI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. CASI Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $1.573. CASI Pharmaceuticals's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2025-03-30), CASI Pharmaceuticals's share price is $2.1474. CASI Pharmaceuticals's Median PS Value is $0.00. Therefore, CASI Pharmaceuticals's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for CASI Pharmaceuticals's Median PS Value or its related term are showing as below:
The historical data trend for CASI Pharmaceuticals's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
CASI Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, CASI Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's Price-to-Median-PS-Value falls into.
CASI Pharmaceuticals's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 1.573 | * | 0 | |
= | 0.00 |
10-Year Median PS Ratio is 0.
CASI Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.573.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals (NAS:CASI) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
CASI Pharmaceuticals's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 2.1474 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of CASI Pharmaceuticals's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
James Huang | director | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Wei-wu He | director, 10 percent owner, officer: Chairman and CEO | ENTREMED, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Weihao Xu | officer: Chief Financial Officer | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Larry Zhang | officer: President | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Shrotriya Rajesh C Md | director | 157 TECHNOLOGY DRIVE, IRVINE CA 92618 |
Salisbury Franklin Cary Jr | director | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Yue Alexander Wu | director | C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121 |
Wealth Strategy Holding Ltd | 10 percent owner | LEVEL 12, INTERNATIONAL COMMERCE CENTRE, 1 AUSTIN ROAD WEST, HONG KONG K3 HK |
Alexander A Zukiwski | officer: Chief Medical Officer | 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822 |
George Chi | officer: Chief Financial Officer | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Dapeng Li | 10 percent owner | BUILDING 1037,XIHU GOLF,, ZHIGANG ROAD 200, HANGZHOU, ZHEJANG F4 310008 |
Idg-accel China Growth Fund Iii L.p. | 10 percent owner | UNIT 5505, 55TH FLOOR, THE CENTER, 99 QUEEN'S ROAD K3 00000 |
Spectrum Pharmaceuticals Inc | 10 percent owner | 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052 |
Sparkle Byte Ltd | 10 percent owner | P.O. BOX 957, OFFSHORE INCORPORATIONS CENTRE ROAD TOWN, TORTOLA D8 00000 |
Ken Ren | director, officer: CEO and Director | 3RD FL, BOROUGH A, BLOCK A, NO. 181 SOUTH TAIBAI ROAD, XI'AN, SHAANXI PROVINCE F4 710065 |
From GuruFocus
By PRNewswire • 08-01-2023
By PRNewswire • 06-26-2024
By PRNewswire PRNewswire • 12-15-2022
By PRNewswire • 09-04-2024
By PRNewswire • 11-14-2023
By PRNewswire • 04-08-2024
By PRNewswire PRNewswire • 03-21-2023
By PRNewswire PRNewswire • 01-06-2023
By PRNewswire • 07-08-2024
By PRNewswire • 02-16-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.